98%
921
2 minutes
20
Uropathogenic Escherichia coli (UPEC) are among the first pathogens to colonise in catheter and non-catheter-associated urinary tract infections. However, these infections are often polymicrobial, resulting in multi-species infections that persist by forming biofilms. Living within these highly antimicrobial tolerant communities, bacteria can establish intra- and inter-specific interactions, including quorum sensing (QS)-mediated signalling mechanisms, which play a key role in biofilm establishment and maturation. Although E. coli does not produce N-acylhomoserine lactones (AHLs), it possesses an orphan LuxR-type receptor, SdiA, which can bind these QS signals released by other Gram-negative bacteria, modulating several virulence-associated phenotypes including biofilm formation. Despite biofilms being considered a major public health challenge due to their persistence and resilience, the knowledge of the SdiA role in biofilm regulation and UPEC fitness in mixed biofilms is limited compared to enteropathogenic E. coli. We have used a ΔsdiA mutant and phenotypic analysis to investigate the SdiA influence on UPEC single and mixed biofilms with Pseudomonas aeruginosa. SdiA was found to inhibit UPEC biofilm and addition of AHLs enhanced E. coli surface colonisation via SdiA-mediated de-repression of biofilm. We also confirmed the low specificity of SdiA for AHLs, demonstrating the SdiA importance in tightly regulating the UPEC free-living and biofilm-associated lifestyles.
Download full-text PDF |
Source |
---|---|
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0328837 | PLOS |
IJID Reg
September 2025
Moriah Institute of Science and Education (MISE), Hospital Moriah, São Paulo, Brazil.
Objectives: Urinary tract infections (UTIs) are among the most common infections worldwide, with being the predominant pathogen, particularly, in women. The rise of antimicrobial resistance, especially due to extended-spectrum β-lactamase-producing , has significantly limited treatment options, posing a serious public health concern. Rational antibiotic use and continuous monitoring of resistance patterns are essential to address this challenge.
View Article and Find Full Text PDFBMC Infect Dis
September 2025
Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
Background: Escherichia coli ST131 and clade H30Rx are the most prevalent extended-spectrum β-lactamase-producing E. coli (ESBL-EC) causing bacteremia and urinary tract infections globally and in Sweden. Previous studies have linked ST131-H30Rx with septic shock and mortality, as well as prolonged carriage.
View Article and Find Full Text PDFNPJ Biofilms Microbiomes
September 2025
Research Group Medical Systems Biology, University Hospital Schleswig-Holstein Campus Kiel, 24105 Kiel University, Kiel, Schleswig-Holstein, Germany.
Urinary tract infections (UTIs) are among the most common bacterial infections and are increasingly complicated by multidrug resistance (MDR). While Escherichia coli is frequently implicated, the contribution of broader microbial communities remains less understood. Here, we integrate metatranscriptomic sequencing with genome-scale metabolic modeling to characterize active metabolic functions of patient-specific urinary microbiomes during acute UTI.
View Article and Find Full Text PDFPLoS One
September 2025
Department of Microbiology and Parasitology, Faculty of Biology - Aquatic One Health Research Center (iARCUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Uropathogenic Escherichia coli (UPEC) are among the first pathogens to colonise in catheter and non-catheter-associated urinary tract infections. However, these infections are often polymicrobial, resulting in multi-species infections that persist by forming biofilms. Living within these highly antimicrobial tolerant communities, bacteria can establish intra- and inter-specific interactions, including quorum sensing (QS)-mediated signalling mechanisms, which play a key role in biofilm establishment and maturation.
View Article and Find Full Text PDFAntimicrob Agents Chemother
September 2025
GSK, Collegeville, Pennsylvania, USA.
Gepotidacin, a novel, bactericidal, first-in-class triazaacenaphthylene antibacterial, was noninferior to nitrofurantoin in two pivotal trials (EAGLE-2 and EAGLE-3) in females with uncomplicated urinary tract infections (uUTIs). Using pooled data, gepotidacin activity and clinical efficacy were evaluated for subsets of molecularly characterized isolates in the microbiological Intent-to-Treat population. The subsets of isolates were characterized based on phenotypic/MIC criteria; all microbiological failure isolates were also characterized.
View Article and Find Full Text PDF